Please login to the form below

Not currently logged in
Email:
Password:

SD-809

This page shows the latest SD-809 news and features for those working in and with pharma, biotech and healthcare.

FDA sets August review date for Teva's movement disorder drug

FDA sets August review date for Teva's movement disorder drug

Patients with the movement disorder tardive dyskinesia (TD) could have a first approved treatment if the FDA clears Teva's SD-809 candidate later this year. ... Teva needs that kind of return, having forked out $3.5bn for SD-809's developer Auspex Pharma

Latest news

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn. ... Originally reported in DW Issue 57 [March 2015], Teva paid a 42% premium to acquire the company, which included other pipeline

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics